<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>doc1.txt
<TEXT>
<PAGE>


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 8-K-A


                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                 Date of Event Requiring Report:  March 11, 2003


                      ADVANCED PLANT PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


               Delaware             59-2762023             000-28459
      (State of Incorporation) (Commission File Number)  (IRS Employer
                                                         Identification #)


                  43 West 33rd Street, New York, New York 10001
                  --------------------------------------------
                    (Address of Principal Executive Offices)

                                 (212) 695-3334
                    ----------------------------------------
              (Registrant's telephone number, including area code)


<PAGE>


ITEM  4.          CHANGES  IN  REGISTRANT'S  CERTIFYING  ACCOUNTANT

     (a)     On  March  11,  2003, the Registrant was officially notified by its
Independent Auditor, Michael C. Finklestein, C.P.A., that it had resigned as the
Independent  Auditor  of  the  Registrant.  The  Board of Directors accepted the
resignation  as  of  March  11,  2003.

     During  his  tenure,  Michael  C.  Finklestein,  C.P.A.,  issued reports on
Registrant's  financial  statements  up  to  December  31,  2001,  that  neither
contained  an  adverse  opinion  or  disclaimer  of  opinion however, Michael C.
Finkelstein,  C.P.A.'s  report for the year ended December 31, 2001 was modified
as  to  the  uncertainty  of  a  going  concern.

     During  the  period  including  the  two  most  recent fiscal years and any
subsequent  interim  period  preceding  this  action,  there was no disagreement
between  Registrant  and  Michael  C.  Finklestein,  C.P.A.  on  any  matter  of
accounting  principals  or  practices,  financial  statement disclosure or audit
scope  and procedure, which disagreement(s), if not resolved to the satisfaction
of  Michael  C. Finklestein, C.P.A., would have caused them to make reference to
the  subject  matter  of  the  disagreement  in  connection  with  its  report.

     The  disclosure  contained  herein  has  been  submitted  to  Michael  C.
Finklestein,  C.P.A.  for  its  review  and  for  them to have an opportunity to
comment  on  the  disclosure.  A copy of the letter is attached as Exhibit 16 to
this  report.

     (b)     Effective March 11, 2003, Livingston, Wachtell & Co., LLP, has been
retained  as  independent  auditor  of  Advanced Plant Pharmaceutical, Inc., the
Registrant,  and  was  retained as independent auditor of the registrant for the
fiscal  year  ending December 31, 2002.  Prior to the engagement, Registrant did
not  consult  with  Livingston, Wachtell & Co., LLP regarding the application of
accounting  principles  to a specified transaction, or the type of audit opinion
that  may  be rendered with respect to the Registrant's financial statements, as
well  did not consult with Livingston, Wachtell & Co. LLP, as to the application
of accounting principles to a specific completed or contemplated transaction, or
the  type  of audit opinion that might be rendered on the Registrant's financial
statements  and either written or oral advice was provided that was an important
factor considered by the Registrant in reaching a decision as to the accounting,
auditing  or  financial  reporting  issue

     (c)     The  filing  of  the Registrant of a Current Report on Form 8-K, on
April  7,  2003,  contained disclosure that was inaccurate and not complete.  In
the  8-K-A,  filed  on  said  date,  it  stated  that  during  the period of his
engagement,  Michael  C.  Finkelstein,  C.P.A.,  advised the Registrant that the
internal  controls  necessary  to  develop reliable financial statements did not
exist.  In fact, no such report was issued by Michael C. Finkelstein, C.P.A.  In
his  letter,  annexed  as  Exhibit 16 to said Current Report, he stated that the
there  were no comments or disagreements with the statements made therein.  That
statement was incorrect.  There have been no such report made by Mr. Finkelstein
to  the  Registrant.

                                        2
<PAGE>


EXHIBITS

Exhibit16     Letter  of  Michael  C.  Finklestein,  C.P.A.


SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
Registrant  has  duly caused this Current Report on Form 8-K to be signed on its
behalf  by  the  undersigned  hereunto  duly  authorized.

     By:  /s/  David  Lieberman
     ---------------------------------
          David  Lieberman
          President

Date:     May  28,  2003

                                        3
<PAGE>

</TEXT>
</DOCUMENT>